The efficacy of somatostatin analogues in the treatment of diabetic retinopathy and thyroid eye disease

References

• AielloLPPierceEAFoleyED1995Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteinsProc Natl Acad Sci USA9210457617479819
   PubMed Web of Science ®Google Scholar
• BahnRSHeufelderAE1993Pathogenesis of Graves’ ophthalmopathyN Engl J Med3291468758413459
   PubMed Web of Science ®Google Scholar
• BartleyGBFatourechiVKadrmasEF1995The incidence of Graves‘ ophthalmopathy in Olmsted County, MinnesotaAm J Ophthalmol120511177573310
   PubMed Web of Science ®Google Scholar
• BoehmBOLangGKJehlePM2001Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathyHorm Metab Res33300611440277
   PubMed Web of Science ®Google Scholar
• BoehmBOLustigRH2002Use of somatostatin receptor ligands in obesity and diabetic complicationsBest Pract Res Clin Gastroenterol1649350912079271
   PubMed Web of Science ®Google Scholar
• BrunsCShiVHoyerD2000Somatostatin receptors and the potential use of Sandostatin to interfere with vascular remodellingEur J Endocrinol143S3711068933
   PubMed Web of Science ®Google Scholar
• BrunsCLewisIBrinerU2002SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profileEur J Endocrinol1467071611980628
   PubMed Web of Science ®Google Scholar
• BuenoLFerreJP1982Central regulation of intestinal motility by somatostatin and cholecystokinin octapeptideScience26142796124037
   PubMed Web of Science ®Google Scholar
• ChangTCKaoSCHuangKM1992Octreotide and Graves’ ophthalmopathy and pretibial myxoedemaBr Med J3041581737161
   PubMed Web of Science ®Google Scholar
• ChangTCLiaoSL2006Slow-release lanreotide in Graves’ ophthalmopathy: A double-blind randomized, placebo-controlled clinical trialJ Endocrinol Invest294132216794364
   PubMed Web of Science ®Google Scholar
• CroxenRBaarsmaGSKuijpersRW2004Somatostatin in diabetic retinopathyPediatr Endocrinol Rev1Suppl 35182416444186
   PubMedGoogle Scholar
• DasguptaP2004Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesisPharmacol Ther102618515056499
   PubMed Web of Science ®Google Scholar
• De BellisASansoneDCoronellaC2005Serum antibodies to collagen XIII: a further good marker of active Graves’ ophthalmopathyClin Endocrinol (Oxf)6224915638866
   PubMed Web of Science ®Google Scholar
• DickinsonAJVaidyaBMillerM2004Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathyJ Clin Endocrinol Metab8959101515579735
   PubMed Web of Science ®Google Scholar
• DurakIDurakHErginM1995Somatostatin receptors in the orbitsClin Nucl Med20237427750218
   PubMed Web of Science ®Google Scholar
• EfthymiouEBougouliaMKrassasGE1995The effect of somatostatin in the treatment of diabetic retinopathy [in Greek]Hel Diabet Chron822732
   Google Scholar
• EpelbaumJDournaudPFodorM1994The neurobiology of somatostatinCrit Rev Neurobiol825447907281
   PubMedGoogle Scholar
• FerjouxGBousquetCCordelierP2000Signal transduction of somatostatin receptors negatively controlling cell proliferationJ Physiol Paris942051011087998
   PubMed Web of Science ®Google Scholar
• GopinathBMusselmanRAdamsCL2006Study of serum antibodies against three eye muscle antigens and the connective tissue antigen collagen XIII in patients with graves’ disease with and without ophthalmopathy: correlation with clinical featuresThyroid169677417042681
   PubMed Web of Science ®Google Scholar
• GrantMBMamesRCooperR1996Octreotide does not prevent progression of diabetic retinopathy (Abstract)Invest Ophthalmol Vis Sci37S958
   Web of Science ®Google Scholar
• GrantMBMamesRNFitzgeraldC2000The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled studyDiabetes Care23504910857943
   PubMed Web of Science ®Google Scholar
• HoflandLJLambertsSW2003The pathophysiological consequences of somatostatin receptor internalization and resistanceEndocr Rev24284712588807
   PubMed Web of Science ®Google Scholar
• KastelanSZjacic-RotkvicVKastelanZ2007Could diabetic retinopathy be an autoimmune disease?Med Hypotheses681016817125935
   PubMed Web of Science ®Google Scholar
• KhooDHCTanYTFokACK1995Octreotide in the management of Graves’ ophthalmopathy – changes in insulin-like growth factor 1 levels do not predict clinical responseAm J Clin Research43342
   Google Scholar
• KirkegaardCNorgaardKSnorgaardO1990Effect of one year continuous subcutaneous infusion of a somatostatin analogue, octreotide, on early retinopathy, metabolic control and thyroid function in Type I (insulin-dependent) diabetes mellitusActa Endocrinol (Copenh)122766722197845
   PubMedGoogle Scholar
• KleinRKleinBEMossSE1984aThe Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 yearsArch Ophthalmol10252066367724
   PubMed Web of Science ®Google Scholar
• KleinRKleinBEMossSE1984bThe Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more yearsArch Ophthalmol102527326367725
   PubMed Web of Science ®Google Scholar
• KohnerEM1993Diabetic retinopathyBr Med J307119598251848
   PubMed Web of Science ®Google Scholar
• KrassasGEDoumasAKaltsasT1999Somatostatin receptor scintigraphy before and after treatment with somatostatin analogues in patients with thyroid eye diseaseThyroid9475210037076
   PubMed Web of Science ®Google Scholar
• KrassasGEDumasAPontikidesN1995Somatostatin receptor scintigraphy and octreotide treatment in patients with thyroid eye diseaseClin Endocrinol (Oxf)42571807634496
   PubMed Web of Science ®Google Scholar
• KrassasGEHeufelderAE2001Immunosuppressive therapy in patients with thyroid eye disease: an overview of current conceptsEur J Endocrinol1443111811275939
   PubMed Web of Science ®Google Scholar
• KrassasGEKaltsasTDumasA1997Lanreotide in the treatment of patients with thyroid eye diseaseEur J Endocrinol136416229150703
   PubMed Web of Science ®Google Scholar
• KrassasGEWiersingaWM2005Thyroid eye disease: current concepts and the EUGOGO perspectivesThyroid International4117
   Google Scholar
• KrassasGE2001Thyroid eye disease in children and adolescents–new therapeutic approachesJ Pediatr Endocrinol Metab149710011220712
   PubMed Web of Science ®Google Scholar
• KrassasGE2004Somatostatin analogs: a new tool for the management of Graves’ ophthalmopathyJ Endocrinol Invest27281715165005
   PubMed Web of Science ®Google Scholar
• KrassasGEBoboridisK2006Recent developments in the medical treatment of thyroid eye diseaseOrbit251172216754220
   PubMedGoogle Scholar
• KrejsGJ1986Physiological role of somatostatin in the digestive tract: gastric acid secretion, intestinal absorption, and motilityScand J Gastroenterol Suppl11947532876506
   PubMedGoogle Scholar
• KuijpersRWBaarsmaSvan HagenPM1998Treatment of cystoid macular edema with octreotideN Engl J Med33862469480445
   PubMed Web of Science ®Google Scholar
• KungAWMichonJTaiKS1996The effect of somatostatin versus corticosteroid in the treatment of Graves’ ophthalmopathyThyroid638148936659
   PubMed Web of Science ®Google Scholar
• LauderHSellersLAFanTP1997Somatostatin sst5 inhibition of receptor mediated regeneration of rat aortic vascular smooth muscle cellsBr J Pharmacol122663709375962
   PubMed Web of Science ®Google Scholar
• LewinMJ1986Somatostatin receptorsScand J Gastroenterol Suppl1194262876505
   PubMedGoogle Scholar
• LewinMJ1992The somatostatin receptor in the GI tractAnnu Rev Physiol54455681348612
   PubMed Web of Science ®Google Scholar
• LiuQReubiJCWangY2003In vivo phosphorylation of the somatostatin 2A receptor in human tumorsJ Clin Endocrinol Metab886073914671213
   PubMed Web of Science ®Google Scholar
• MakhloufGMSchubertML1990Gastric somatostatin: a paracrine regulator of acid secretionMetabolism39138421976209
   PubMed Web of Science ®Google Scholar
• MalletBVialettesBHarocheS1992Stabilization of severe proliferative diabetic retinopathy by long-term treatment with SMS 201–995Diabete Metab18438441297600
   PubMed Web of Science ®Google Scholar
• OzataMBoluESengulA1996Effects of octreotide treatment on Graves’ ophthalmopathy and circulating sICAM-1 levelsThyroid628388875747
   PubMed Web of Science ®Google Scholar
• PatelYC1999Somatostatin and its receptor familyFront Neuroendocrinol201579810433861
   PubMed Web of Science ®Google Scholar
• ReisineTBellGI1995Molecular biology of somatostatin receptorsEndocrine Rev16427428521788
   PubMed Web of Science ®Google Scholar
• SilerTMYenSCValeW1974Guillemin. Inhibition by somatostatin on the release of TSH induced in man by thyrotropin-releasing factorJ Clin Endocrinol Metab3874254207367
   PubMed Web of Science ®Google Scholar
• StanMNGarrityJABradleyEA2006Randomized, double-blind, placebo-controlled trial of long-acting release octreotide for treatment of Graves’ ophthalmopathyJ Clin Endocrinol Metab9148172416984988
   PubMed Web of Science ®Google Scholar
• StrnadJEpplerCMCorbettM1993The rat SSTR2 somatostatin receptor subtype is coupled to inhibition of cyclic AMP accumulationBiochem Biophys Res Commun191968768096694
   PubMed Web of Science ®Google Scholar
• ThornerMOVanceMLHartmanML1990Bowers. Physiological role of somatostatin on growth hormone regulation in humansMetabolism394021976218
   PubMed Web of Science ®Google Scholar
• UngerRHDobbsREOrciL1978Insulin, glucagon, and somatostatin secretion in the regulation of metabolismAnnu Rev Physiol4030743205166
   PubMed Web of Science ®Google Scholar
• UysalARCorapciogluDTonyukukVC1999Effect of octreotide treatment on Graves’ ophthalmopathyEndocr J46573710580750
   PubMed Web of Science ®Google Scholar
• van HagenPMBaarsmaGSMooyCM2000Somatostatin and somatostatin receptors in retinal diseasesEur J Endocrinol143suppl 1S43S5111068939
   PubMed Web of Science ®Google Scholar
• WemeauJLCaronPBeckersA2005Octreotide (long-acting release formulation) treatment in patients with graves’ orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind studyJ Clin Endocrinol Metab90841815562016
   PubMed Web of Science ®Google Scholar
• YuukiTKandaTKimuraY2001Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathyJ Diabetes Complications15257911522500
   PubMed Web of Science ®Google Scholar